πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11708352

Anti-cancer compounds

The Regents of the University of California Β· Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11697676

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11692032

Anti-LAG3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685784

Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of th

China Medical University Hospital Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672872

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672785

Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673967

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667701

Anti-PfRH5 antibodies and antigen-binding fragments thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655307

Anti-doublecortin-like kinase 1 antibodies and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655286

Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and met

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654187

Horn fly protein as active antigen in anti-horn fly vaccine for protection of bovines agai

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648318

Anti-transferrin receptor (TFR) antibody and uses thereof

Dyne Therapeutics, Inc. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648307

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649273

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633501

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629195

Anti-IL2 receptor gamma antigen-binding proteins

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11623010

Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition a

BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608380

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603413

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596688

Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596690

Stabilized formulations containing anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted